Karyopharm Therapeutics Inc.
KPTI · XNASCIK 1503802fmd_0RRPECTAQQ9HK6Q401H66V94J9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 22, 2008 to Jun 30, 2026, 62 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 2 | 30 | 41 | 108 | 210 | 157 | 146 | 145 | 146 |
| Research and development | 87 | 107 | 161 | 122 | 151 | 161 | 149 | 139 | 143 | 126 |
| Selling, general and administrative | – | 25 | 49 | 105 | 126 | 144 | 145 | 132 | 115 | 105 |
| Total operating expenses | 111 | 132 | 210 | 230 | 280 | 308 | 299 | 276 | 265 | 237 |
| Operating income | (111) | (131) | (180) | (189) | (172) | (98) | (142) | (130) | (119) | (91) |
| Interest expense | – | – | 2 | 16 | 27 | 26 | 25 | 24 | 37 | 46 |
| Interest and investment income | 1 | 2 | 4 | 5 | 3 | 1 | 2 | 11 | 7 | 3 |
| Other non-operating income (expense) | 1 | 2 | 2 | (10) | (24) | (26) | (23) | (13) | 43 | (105) |
| Income before taxes | (109) | (129) | (178) | (200) | (196) | (124) | (165) | (143) | (76) | (196) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (110) | (129) | (178) | (200) | (196) | (124) | (165) | (143) | (76) | (196) |
| Net income | (110) | (129) | (178) | (200) | (196) | (124) | (165) | (143) | (76) | (196) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (118) | – |